Holen Sie sich die Stockscreener-App
236.97
1.26%
2.96
Handel nachbörslich:
236.97
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt DVA?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$234.01
Offen:
$234.34
24-Stunden-Volumen:
545.70K
Relative Volume:
0.65
Marktkapitalisierung:
$15.21B
Einnahmen:
$13.84B
Nettoeinkommen (Verlust:
$1.10B
KGV:
22.75
EPS:
10.4185
Netto-Cashflow:
$1.49B
1W Leistung:
+1.79%
1M Leistung:
+12.53%
6M Leistung:
+126.25%
1J Leistung:
+65.27%
1-Tages-Spanne:
$233.35
$238.53
1-Wochen-Bereich:
$225.17
$239.44
52-Wochen-Spanne:
$101.00
$239.64
Davita Inc Stock (DVA) Company Profile
Firmenname
Davita Inc
Sektor
Branche
Telefon
310-536-2668
Adresse
2000 16TH STREET, DENVER, CO
Compare DVA vs HCA, THC, FMS, EHC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DVA
Davita Inc
|
236.97 | 15.02B | 13.84B | 1.10B | 1.49B | 10.42 |
HCA
Hca Healthcare Inc
|
371.18 | 85.57B | 76.39B | 7.81B | 7.93B | 29.08 |
THC
Tenet Healthcare Corp
|
194.91 | 17.16B | 21.46B | 2.65B | 3.35B | 19.23 |
FMS
Fresenius Medical Care Ag Adr
|
24.11 | 12.94B | 22.44B | 1.35B | 2.03B | 1.9002 |
EHC
Encompass Health Corp
|
112.21 | 11.16B | 6.07B | 793.80M | 464.40M | 5.9914 |
Davita Inc Stock (DVA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-03-06 | Eingeleitet | Barclays | Equal Weight |
| 2023-08-07 | Hochstufung | UBS | Neutral → Buy |
| 2022-11-01 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2022-10-31 | Herabstufung | UBS | Buy → Neutral |
| 2022-08-19 | Fortgesetzt | UBS | Buy |
| 2022-06-21 | Bestätigt | BofA Securities | Underperform |
| 2021-09-10 | Eingeleitet | Cowen | Market Perform |
| 2021-08-12 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2021-03-26 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-01-05 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-01-24 | Hochstufung | Goldman | Neutral → Buy |
| 2019-11-07 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2019-10-25 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2019-09-11 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2019-07-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-01-08 | Hochstufung | UBS | Sell → Neutral |
| 2019-01-03 | Eingeleitet | Deutsche Bank | Buy |
| 2018-12-14 | Eingeleitet | Barclays | Overweight |
| 2018-11-28 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-11-16 | Eingeleitet | UBS | Sell |
| 2018-11-08 | Herabstufung | Raymond James | Strong Buy → Mkt Perform |
| 2018-09-13 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2018-01-04 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2017-12-12 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2017-12-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2017-12-07 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2017-11-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2017-10-09 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2017-06-26 | Herabstufung | Jefferies | Buy → Hold |
| 2016-12-13 | Herabstufung | Robert W. Baird | Outperform → Neutral |
Alle ansehen
Davita Inc Aktie (DVA) Neueste Nachrichten
DaVita stock benefits from expanding community-based kidney care - MSN
DaVita stock trades steadily as dialysis margins and leverage stay in focus - ad-hoc-news.de
DaVita stock trades steady as chronic kidney care demand supports earnings trajectory - ad-hoc-news.de
DaVita HealthCare (DVA) Advances While Market Declines: Some Information for Investors - Yahoo Finance
DaVita Inc. stock outperforms competitors on strong trading day - MarketWatch
DaVita Wins Bid To Decertify 1,300-Member Collective - Law360
DaVita: Why We Exited Our Position In Q2 (DVA) - Seeking Alpha
DaVita gains 21.4% in three months: How should you play the stock? - MSN
DaVita stock trades steadily as kidney care margins and cash flow support valuation - ad-hoc-news.de
DaVita HealthCare (DVA) Rises As Market Takes a Dip: Key Facts - Yahoo Finance
DaVita Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
What you need to know ahead of DaVita’s earnings release - MSN
DaVita shares more than double after strong Q1 and court win; analyst sells most shares, rates Hold. - Pluang
DaVita: I Believe This Is Overvalued (NYSE:DVA) - Seeking Alpha
What You Need To Know Ahead of DaVita’s Earnings Release - Yahoo Finance
DaVita Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Truist Raises Price Target on DaVita to $250 From $205, Keeps Hold Rating - Moomoo
Truist Financial Maintains DaVita(DVA.US) With Hold Rating, Raises Target Price to $250 - Moomoo
DaVita expands comprehensive kidney care through dialysis services - MSN
DaVita Company Profile & Introduction - Moomoo
DaVita stock holds steady as kidney care specialist focuses on operations and long-term dialysis dem - ad-hoc-news.de
DaVita Inc. (DVA) Stock Analysis: Strong ROE And Growth Potential In Healthcare Sector - DirectorsTalk Interviews
Exciting News for Farmington: DaVita Maple Valley is Expandi... - Park Hills Daily Journal
DaVita stock reflects steady dialysis demand amid US healthcare focus - ad-hoc-news.de
DVA stock holds steady as dialysis demand underpins the long-term case - ad-hoc-news.de
DaVita HealthCare (DVA) Laps the Stock Market: Here's Why - Yahoo Finance
DaVita Can Return to Long-Term Volume Growth of 2% by 2029, UBS Says - Moomoo
DaVita stock holds steady as kidney care demand supports long term outlook - ad-hoc-news.de
UBS Adjusts Price Target on DaVita to $270 From $235 - marketscreener.com
Everyone Is Watching Greg Abel. But Another Berkshire Hathaway Stock Picker Is Quietly Winning in 2026. - The Motley Fool
DAVITA INC. : BARCLAYS RAISES TARGET PRICE TO $218 FROM $194 - Moomoo
DaVita Inc focus on kidney care operations as investors watch US healthcare demand - Ad-hoc-news.de
DaVita HealthCare (DVA) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance
DaVita stock benefits from strengthening kidney care delivery - MSN
DaVita Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
DaVita Inc. focuses on core dialysis services as investors watch U.S. healthcare trends - ad-hoc-news.de
Barclays Adjusts Price Target on DaVita to $218 From $194 - Moomoo
DaVita (DVA) Q2 2024 earnings summary - Quartr
The DaVita In-Center HemodialysisA core service tailored to U.S. kidney patients - ad-hoc-news.de
DaVita Stock On Fire: Up 13% With 10-Day Winning Streak - Trefis
DaVita Inc. on Track for Record High Close -- Data Talk - Moomoo
DaVita Stock Rockets 13% With 10-Day Winning Streak - Trefis
DaVita Inc. outlines growth path as kidney care demand rises - AD HOC NEWS
DaVita Inc and its role in the US dialysis market. Long-term fundamentals and business model in focu - AD HOC NEWS
DaVita Inc. focuses on kidney care as long-term demand supports the business - ad-hoc-news.de
The DaVita In-Center Hemodialysis Programsteady lifeline for US kidney patients - Ad-hoc-news.de
Insiders At DaVita Sold US$33m In Stock, Alluding To Potential Weakness - Moomoo
DaVita (DVA) Is Up 8.2% After AI Kidney Care Push And Buyback Boosts NarrativeWhat's Changed - simplywall.st
DaVita Inc. focuses on core dialysis services as investors weigh long term care demand - ad-hoc-news.de
DaVita (DVA) Q1 2026 Earnings Call Transcript - Fortune
Price to book forward of DaVita Inc. – NYSE:DVA - TradingView
Finanzdaten der Davita Inc-Aktie (DVA)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.15%
0.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):